
    
      This study will test the hypothesis that micro-doses of a new formulation of stable glucagon,
      Xerisol Glucagon (Xeris Pharmaceuticals), will be non-inferior by pharmacokinetic and
      pharmacodynamic criteria vs. micro-doses of a freshly reconstituted formulation of glucagon
      that has poor stability in solution, Glucagon for Injection (Eli Lilly).
    
  